- Conditions
- Psoriasis
- Interventions
- 80 mg Ixekizumab Dosing Regimens 1, 2, and 3, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Anaheim, California • Bakersfield, California + 31 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 42
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Psoriasis, Obesity
- Interventions
- Ixekizumab, Tirzepatide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 57 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- LY2439821, Placebo
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 37
- States / cities
- Peoria, Arizona • La Mesa, California • Palm Desert, California + 34 more
- Conditions
- Plaque Psoriasis
- Interventions
- Ixekizumab Auto-Injector, Ixekizumab Prefilled Syringe
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 22
- States / cities
- Anaheim, California • Bakersfield, California • Santa Monica, California + 19 more
- Conditions
- Healthy
- Interventions
- Ixekizumab
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Pityriasis Rubra Pilaris
- Interventions
- Ixekizumab
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Rheumatic Disease
- Interventions
- Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
- Drug · Biological
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Psoriasis, Arthritic
- Interventions
- Ixekizumab, Placebo, Adalimumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 34 more
- Conditions
- Psoriasis
- Interventions
- Ixekizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Psoriasis
- Interventions
- Drug Cocktail, Ixekizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Anaheim, California • DeLand, Florida • High Point, North Carolina
- Conditions
- Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
- Interventions
- Ixekizumab Prefilled Syringe
- Drug
- Lead sponsor
- Massachusetts Eye Research and Surgery Institution
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Psoriasis, Overweight or Obesity
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Fremont, California + 35 more
- Conditions
- Psoriasis
- Interventions
- Ixekizumab, Placebo
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 31
- States / cities
- Bakersfield, California • New Haven, Connecticut • Washington D.C., District of Columbia + 28 more
- Conditions
- Psoriasis
- Interventions
- 80 mg ixekizumab Dosing Regimen, 50 mg etanercept, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more
- Conditions
- Psoriatic Arthritis, Overweight or Obesity
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 53
- States / cities
- Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 48 more
- Conditions
- Pyoderma Gangrenosum
- Interventions
- Ixekizumab
- Biological
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Gahanna, Ohio
- Conditions
- Psoriatic Arthritis, Obesity
- Interventions
- Ixekizumab, Tirzepatide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 81
- States / cities
- Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 75 more
- Conditions
- Psoriasis
- Interventions
- Placebo, 50 mg etanercept, 80 mg ixekizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 41
- States / cities
- Anaheim, California • Bakersfield, California • Bell Gardens, California + 38 more
- Conditions
- Bullous Pemphigoid, Pemphigoid
- Interventions
- Ixekizumab
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Psoriasis
- Interventions
- Not listed
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 20,167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2030
- U.S. locations
- 167
- States / cities
- Birmingham, Alabama • Florence, Alabama • Huntsville, Alabama + 164 more
- Conditions
- Psoriasis
- Interventions
- Enstilar
- Drug
- Lead sponsor
- Psoriasis Treatment Center of Central New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- East Windsor, New Jersey
- Conditions
- Lichen Planus Scalp, Lichen Planus, Lichen Planopilaris
- Interventions
- Ixekizumab Auto-Injector
- Drug
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Plaque Psoriasis
- Interventions
- Risankizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • North Little Rock, Arkansas + 16 more
- Conditions
- Plaque Psoriasis
- Interventions
- Ixekizumab, Placebo, Etanercept
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Washington D.C., District of Columbia + 19 more